Navigation Links
Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
Date:8/13/2012

IRVINE, Calif., Aug. 13, 2012 /PRNewswire/ -- Antigen Discovery, Inc. (ADi) today announced that it has received a Phase II Small Business Innovation and Research (SBIR) award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The three-year award, totaling approximately $ 2.5 million, is a continuation of a Phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens. The funds will support a collaborative research effort between ADi and Sanaria, Inc. to use ADi's proteome microarrays to identify biomarkers associated with responses to the administration of Sanaria's malaria products in human trials, including Sanaria® PfSPZ Vaccine (radiation attenuated sporozoites), Sanaria® PfSPZ Challenge (fully infectious sporozoites), and Sanaria® PfSPZ-CVac (PfSPZ Challenge administered with malaria chemoprophylaxis).  An effective malaria vaccine would greatly benefit the billions at risk throughout the world. "By comparing the serum antibody profiles from vaccinees who are protected with those who are not, we aim to identify surrogate antibody biomarkers associated with sporozoite vaccine mediated protection. Such markers are a critically important component of vaccine development," states Dr. Philip Felgner, Principal Investigator, Founder and Chairman of ADi. According to Dr. Stephen L. Hoffman, Sanaria's Founder and Chief Scientific Officer, "This is an unprecedented opportunity to exploit ADi's unique technology to advance our understanding of protective immunity against malaria, and thereby accelerate development and licensure of a highly effective malaria vaccine."   

Additionally, serum samples will be analyzed from clinical studies conducted at Radboud University Nijmengen Medical Center (RUNMC) in the Netherlands, in which volunteers were completely protected after being immunized by the bite of mosquitoes carrying viable (non-irradiated) PfSPZ while taking chloroquine chemoprophylaxis to prevent blood stage infection. The protection lasted for 2 years.  Dr. Robert Sauerwein, director of the RUNMC studies, stated "This is a very exciting opportunity to gain significant insights into how PfSPZ works to provide robust protection against malaria."  

"We are pleased and privileged to have the opportunity to work with the Sanaria and RUNMC teams on this exciting project and grateful for continued support from the NIAID," said Dr. Xiaowu Liang, President and CEO of ADi.  "We aim to develop a diagnostic test that can predict vaccine mediated protection, and to identify antigens that may be used to produce an effective subunit vaccine."

About Antigen Discovery, Inc.

Antigen Discovery, Inc. is a privately owned biotechnology company located in Irvine, California. ADi has a proprietary high throughput proteomics platform technology for biomarker discovery. The company uses and commercializes its innovative proteome microarrays and testing models to facilitate the development of new diagnostic tests, therapeutics and vaccines for infectious disease, autoimmunity, cancer and more. For more information about ADi see http://www.antigendiscovery.com

Contact:

Angela Yee
ayee@antigendiscovery.com

About Sanaria, Inc.

Sanaria's mission is to develop and commercialize live, whole sporozoite vaccines against malaria. Sanaria's sporozoite based products are being tested in clinical trials in the United States, Africa and Europe. Sanaria also makes available to the research community a range of parasitological and entomological reagents and assay services. For more information, see http://www.sanaria.com.

Contact:

Adam Richman, Ph.D.
arichman@sanaria.com 


'/>"/>
SOURCE Antigen Discovery, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
2. Generex Augments Antigen Express Scientific Advisory Board
3. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
4. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
5. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
6. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
7. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
8. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
9. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
10. Turner Construction Company Awarded Fort Irwin Replacement Hospital
11. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
Breaking Medicine News(10 mins):